NCT01699711

Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 87 (actual)
• Sponsor: Parc de Salut Mar · Academic / Other
• Sex: All
• Age: 14 Years – 29 Years
• Healthy volunteers: Not accepted

Summary

Epigallocatechin-3-gallate (EGCG), the major catechin in green tea, is postulated to modulate dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and amyloid beta precursor protein (APP) gene overexpression in the brains of Down syndrome mouse models. The clinical study is aimed at demonstrating that normalization of Dyrk1A and APP functions is a therapeutic approach to improve cognitive performance and decelerate AD (Alzheimer's disease) like progression.

Conditions

• Down Syndrome (DS)

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Epigallocatechin-3-gallate (EGCG)	EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.

Timeline

• Start date: 2012-02-01
• Primary completion: 2014-06-01
• Completion: 2015-03-01
• First posted: 2012-10-04
• Last updated: 2016-02-11

Locations

1 site across 1 country: Spain